BO3482 

In the thigh infection model, four immunosuppressed mice are used per group. An overnight culture of MRSA BB6294 in tryptic soy broth is washed and resuspended in fresh tryptic soy broth. Of this suspension, 0.1 mL is injected into the right thighs of slightly anesthetized mice. The mice receive two doses of drug subcutaneously 2 and 6 h after injection of the test organisms by the following treatment regimens: 10, 20,or 40 mg of BO3482 with 40 mg of cilastatin per kg per dose; 10, 20, or 40 mg of vancomycin per kg per dose; or 40 mg of imipenem with 40 mg of cilastatin per kg per dose. Four hours after the last treatment, the thigh muscles are removed and immediately homogenized in ice-cold 0.9% NaCl with a tissue homogenizer^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Adachi Y, et al. In vitro evaluation of BO-3482, a novel dithiocarbamate carbapenem with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 1997 Oct;41(10):2282-5.  [Content Brief]

  [2]. Nagano R, et al. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997 Oct;41(10):2278-81.  [Content Brief]